Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Pre-Mkt 12-23 05:42:49 EST

779.36

+11.40

+1.48%

High783.60	Low765.09	Vol817.96K
Open765.84	D1 Closing767.96	Amplitude2.41%
Mkt Cap81.91B	Tradable Cap80.51B	Total Shares105.10M
T/O636.80M	T/O Rate0.79%	Tradable Shares103.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":779.36,"timestamp":1766437200000,"preClose":767.96,"halted":0,"volume":817960,"delay":0,"floatShares":103302739,"shares":105099464,"eps":41.59414,"marketStatus":"Pre-Mkt","change":11.4,"latestTime":"12-23 05:42:49 EST","open":765.84,"high":783.6,"low":765.09,"amount":636803781.328,"amplitude":0.024103,"askPrice":784.99,"askSize":38,"bidPrice":767.52,"bidSize":38,"shortable":3,"etf":0,"ttmEps":41.59414,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766500200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":779.36,"dividendRate":0.004517,"postHourTrading":{"tag":"盘后","latestPrice":778,"preClose":779.36,"latestTime":"19:52 EST","volume":92748,"amount":72281111.261,"timestamp":1766451156012},"volumeRatio":0.7044685141184848,"impliedVol":0.3403,"impliedVolPercentile":0.245},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2593461309","title":"BRIEF-Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2593461309","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593461309?lang=en_us&edition=fundamental","pubTime":"2025-12-23 14:02","pubTimestamp":1766469777,"startTime":"0","endTime":"0","summary":"BRIEF-Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial AsthmaDec 23 (Reuters) - Sanofi SA SASY.PA:SANOFI AND REGENERON’S DUPIXENT APPROVED IN JAPAN FOR CHILDREN AGED 6 TO ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nTUA8V1TMS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","LU1917777945.USD","LU2106854487.HKD","LU0320765992.SGD","LU2237438978.USD","LU0823416689.USD","LU1974910355.USD","LU0109394709.USD","LU2089984988.USD","LU2468319806.SGD","LU0053666078.USD","LU0058720904.USD","LU0823434740.USD","LU2362540622.SGD","REGN","LU2023250504.SGD","BK4585","LU0889565916.HKD","LU0289739699.SGD","BK4139","LU0114720955.EUR","BK4588","LU0882574055.USD","LU2362541273.HKD","LU2362541513.USD"],"gpt_icon":0},{"id":"2593613854","title":"Press Release: Sanofi and Regeneron’s Dupixent Approved in Japan for Children Aged 6 to 11 Years With Bronchial Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2593613854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593613854?lang=en_us&edition=fundamental","pubTime":"2025-12-23 14:00","pubTimestamp":1766469602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nTUABRFWDD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0823434583.USD","LU2023250504.SGD","LU0058720904.USD","BK4139","LU2362541513.USD","LU0823434740.USD","BK4585","LU2362540622.SGD","LU1974910355.USD","LU0320765992.SGD","REGN","LU0053666078.USD","LU2089984988.USD","LU2106854487.HKD","LU2468319806.SGD","LU2362541273.HKD","LU0289739699.SGD","LU0823416689.USD","LU1917777945.USD","LU0109394709.USD","LU0882574055.USD","BK4588","LU0114720955.EUR","LU0889565916.HKD","LU2237438978.USD"],"gpt_icon":0},{"id":"2593461556","title":"Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2593461556","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593461556?lang=en_us&edition=fundamental","pubTime":"2025-12-23 14:00","pubTimestamp":1766469600,"startTime":"0","endTime":"0","summary":"Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/23/3209662/0/en/Dupixent-dupilumab-Approved-in-Japan-for-Children-Aged-6-to-11-Years-with-Bronchial-Asthma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","LU2106854487.HKD","LU0289739699.SGD","LU1974910355.USD","LU2089984988.USD","LU0320765646.SGD","REGN","BK4585","LU2468319806.SGD","LU0058720904.USD","LU1829250122.USD","BK4007","LU2023250504.SGD","LU0882574055.USD","LU0109394709.USD","LU2362540622.SGD","LU2362541513.USD","LU0823434583.USD","BP","LU1162221912.USD","LU0889565916.HKD","SNY","BK4139","LU0114720955.EUR","BK4588","LU2362541273.HKD","LU0823434740.USD","LU0053666078.USD","LU2237438978.USD","BK4096","LU0072461881.USD","LU0320765992.SGD","LU1917777945.USD","BK4201","PN","LU0162691827.USD","LU0823416689.USD"],"gpt_icon":0},{"id":"2593453557","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2593453557","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593453557?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:42","pubTimestamp":1766439720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  rallied 1.48% to $779.36 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.64% to 6,878.49 and the Dow Jones Industrial Average  rising 0.47% to 48,362.68.This was the stock's second consecutive day of gains.Regeneron Pharmaceuticals Inc. closed 1.47% below its 52-week high of $790.98, which the company achieved on November 26th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Amgen Inc.  rose 1.22% to $331.39, Moderna Inc.  rose 3.25% to $34.90, and Gilead Sciences Inc.  fell 0.10% to $124.16.Trading volume  remained 274,036 below its 50-day average volume of 1.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 22, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2593585964","title":"Regeneron Announces Presentation at the 44TH Annual J.p. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2593585964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593585964?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:05","pubTimestamp":1766437500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nTUA51JNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJTD4N35.SGD","IE00B3S45H60.SGD","LU2362541273.HKD","IE00BDCRKT87.USD","LU1548497426.USD","LU1894683264.USD","LU0683600562.USD","LU0109394709.USD","SG9999002224.SGD","IE00BLSP4452.SGD","IE00BHPRN162.USD","LU1244550221.USD","LU1668664300.SGD","LU1988902786.USD","LU0889565916.HKD","LU0211326755.USD","LU0942090050.USD","IE00BYXW3230.USD","LU0211328371.USD","LU0820561818.USD","BK4207","LU0964807845.USD","REGN","LU0048584097.USD","LU0256863811.USD","LU1670627923.USD","LU0787776722.HKD","IE00B1BXHZ80.USD","LU0345769128.USD","IE00BKDWB100.SGD","LU2237443382.USD","LU2552382132.HKD","LU0106831901.USD","LU2237443465.HKD","IE00BDRTCR15.USD","LU1917777945.USD","IE00BN8TJ469.HKD","LU1119994496.HKD","LU0211331839.USD","LU0943347566.SGD","LU1244550577.SGD","LU0267386448.USD","LU2456880835.USD","LU0251132253.USD","LU2106854487.HKD","BK4550","LU0170899867.USD","LU0070302665.USD","LU2089984988.USD","LU0689472784.USD"],"gpt_icon":0},{"id":"2593589074","title":"Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2593589074","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593589074?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:05","pubTimestamp":1766437500,"startTime":"0","endTime":"0","summary":"TARRYTOWN, N.Y., Dec.  22, 2025  (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/22/3209548/0/en/Regeneron-Announces-Presentation-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4534","LU0320765992.SGD","LU1244550494.USD","LU1974910355.USD","LU2237438978.USD","BK4127","BK4516","LU0006306889.USD","LU0158827948.USD","HCSG","LU0795875086.SGD","BK4137","XBI","BK4504","IE00BZ1G4Q59.USD","LU1917777945.USD","BK4588","XLV","LU1732799900.SGD","BK4139","LU1791710582.SGD","LU2357305700.SGD","LU0314104364.USD","LU0912757837.SGD","LU2133065610.SGD","LU0882574139.USD","LU1074936037.SGD","LU2362540622.SGD","LU0058720904.USD","LU0320765646.SGD","BK4585","LU2028103732.USD","LU0114720955.EUR","LU1548497426.USD","LU1720051017.SGD","LU0053666078.USD","LU2106854487.HKD","REGN","LU0109394709.USD","LU1244550221.USD","LU1720051108.HKD","LU0234570918.USD","LU2362541513.USD","LU0289739699.SGD","LU0823434740.USD","LU2362541273.HKD","LU2089284900.SGD","LU1791710400.SGD","LU0267386448.USD"],"gpt_icon":0},{"id":"1121603458","title":"Merck (MRK.US), Bristol-Myers Squibb (BMY.US), and Other Pharma Giants Agree to Lower U.S. Drug Prices in Exchange for Tariff Exemptions and Policy Support","url":"https://stock-news.laohu8.com/highlight/detail?id=1121603458","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121603458?lang=en_us&edition=fundamental","pubTime":"2025-12-20 07:20","pubTimestamp":1766186452,"startTime":"0","endTime":"0","summary":"Amid President Trump's push to link U.S. drug prices with lower-cost international markets, several major U.S. and European pharmaceutical companies have recently reached an agreement with the White...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"2acbaf8fbf691a451fa9ea170ee88816","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LU1941712264.USD","LU0965509010.AUD","LU0868494617.USD","LU1983299246.USD","LU0203345920.USD","LU1868836757.USD","NVO","IE0002141913.USD","LU0321505868.SGD","LU1261432733.SGD","LU2360032135.SGD","SG9999014542.SGD","LU1093756325.SGD","LU0203347892.USD","SG9999013999.USD","LU0320765646.SGD","LU1061106388.HKD","LU1974910355.USD","IE00BBT3K403.USD","ABBV","LU0321505439.SGD","LU0320765489.SGD","LU1718418525.SGD","IE00BFTCPJ56.SGD","LU2361044949.HKD","LU1430594728.SGD","LU2112291526.USD","SG9999014575.USD","MRK","IE000M9KFDE8.USD","NVS","SG9999015341.SGD","BK4559","LU0265550359.USD","LU1037948897.HKD","LU2324357040.USD","IE00BLSP4239.USD","LU0211331839.USD","LLY","IE0009355771.USD","LU0306807586.USD","LU1699723380.USD","LU0006306889.USD","LU0648001328.SGD","LU0267386448.USD","LU1868837300.USD","BK4550","LU1032466523.USD","SG9999001440.SGD","BK4533","IE00BSNM7G36.USD","SG9999002224.SGD","LU2242652126.USD","LU1868836914.USD","BK4516","LU1162221912.USD","LU0130517989.USD","LU1934455277.USD","BK4588","LU1868836591.USD","LU0985320562.USD","BK4581","LU2125154778.USD","LU0965509283.SGD","LU1037948541.HKD","LU1868837136.USD","ROG","SG9999014559.SGD","IE00BJJMRZ35.SGD","LU1093756168.USD","SG9999002232.USD","LU0861579265.USD","LU0882574055.USD","LU0225284248.USD","LU1066053197.SGD","BK4585","LU0306806265.USD","LU0208291251.USD","LU1323610961.USD","LU2023250504.SGD","LU2023250843.SGD","LU0265550946.USD","JNJ","LU1035773651.USD","LU0266013472.USD","LU0096364046.USD","LU2133065610.SGD","SG9999001176.USD","IE00BLSP4452.SGD","LU0098860793.USD","LU0237698245.USD","LU1066051225.USD","LU0477156953.USD","REGN","LU0289739699.SGD","LU0114720955.EUR","LU1291159041.SGD","LU1989771016.USD","SG9999015358.SGD","LU0058720904.USD","BK4534","IE00BJT1NW94.SGD","LU1934455194.USD","LU1057294990.SGD","IE00BN8TJ469.HKD","LU1934455863.HKD","LU1066051498.USD","LU0106261372.USD","LU0122379950.USD","LU1116320737.USD","LU2361044865.SGD","BK4532","IE00BFXG1179.USD","LU0070302665.USD","LU0238689110.USD","SGXZ57979304.SGD","LU1670711123.USD","LU0234572021.USD","LU1074936037.SGD","LU2361045086.USD","LU2468319806.SGD","LU0456855351.SGD","LU1929549753.HKD","PFE","LU1023059063.AUD","LU1201861249.SGD","LU1670711040.USD","LU1670710588.SGD","LU2461242641.AUD","LU0130102774.USD","LU1585245621.USD","LU0225771236.USD","LU1941712348.USD","LU1989772840.SGD","SNY","LU0061475181.USD","LU1989772923.USD","IE00B1BXHZ80.USD","LU1069347547.HKD","LU0965508806.USD","BMY","IE00B2B36J28.USD","LU1917777945.USD","SG9999001176.SGD","LU2242646821.SGD","LU0965509101.SGD","LU0985481810.HKD","BK4007","IE00B4R5TH58.HKD","GSK","AMGN","LU2125154935.USD","04332","LU1066051811.HKD","LU0980610538.SGD","SG9999014567.USD","AZN","LU2106854487.HKD","GILD","LU1116320901.HKD","LU1670710661.SGD","LU2089984988.USD"],"gpt_icon":1},{"id":"2592160160","title":"Trump, Nine Pharmaceutical Companies Strike Deal to Cut Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2592160160","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592160160?lang=en_us&edition=fundamental","pubTime":"2025-12-20 07:07","pubTimestamp":1766185675,"startTime":"0","endTime":"0","summary":"Drugmakers to cut prices on most drugs sold to the Medicaid programU.S. patients pay the most for prescription medicines(Reuters) - U.S. President Donald Trump and nine major pharmaceutical companies...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"2acbaf8fbf691a451fa9ea170ee88816","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL6N3XP0UP:3","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0792757196.USD","SG9999018865.SGD","IE00BK4W5M84.HKD","JNJ","LU1868836591.USD","AMGN","LU1170363599.USD","LU1935042991.SGD","MRK","LU1051770623.HKD","BMY","LU1196500208.SGD","LU2023251221.USD","LU2746668461.USD","PFE","SG9999015978.USD","LLY","LU2168564495.EUR","LU2237443382.USD","LU1868836914.USD","LU1868837300.USD","LU2462157665.USD","SG9999015341.SGD","IE00B3T34201.USD","LU0310800965.SGD","LU0354030511.USD","LU0432979614.USD","LU1059921491.USD","LU2362541513.USD","LU0256863902.USD","LU0130517989.USD","LU1280957306.USD","REGN","LU0310800379.SGD","LU0575583348.USD","LU0130102774.USD","LU2491050071.SGD","ABBV","LU0957799991.USD","SG9999014575.USD","GILD","LU2237443978.SGD","IE00BFXG1179.USD","LU1934455863.HKD","LU1366192091.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2592669871","title":"Goldman Sachs Adjusts PT on Regeneron Pharmaceuticals to $807 From $788, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2592669871","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592669871?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:28","pubTimestamp":1766143698,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $802.96, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PT","REGN"],"gpt_icon":0},{"id":"2592165488","title":"Several top drugmakers to lower US prices for some drugs-sources","url":"https://stock-news.laohu8.com/highlight/detail?id=2592165488","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592165488?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:00","pubTimestamp":1766142000,"startTime":"0","endTime":"0","summary":"Several top drugmakers to lower US prices for some drugs-sourcesBy Michael Erman, Jarrett Renshaw and Patrick Wingrove","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL1N3XO0QU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0857590862.USD","LU1988902786.USD","BMY","LU0006306889.USD","LU0477156953.USD","IE00BJJMRX11.SGD","LU2347655156.SGD","LU0203347892.USD","AZN.UK","LU1162221912.USD","SG9999015952.SGD","LU0029864427.USD","JNJ","LU0052756011.USD","BK4139","LU1066053197.SGD","LU0882574055.USD","BK4566","REGN","LU0965509283.SGD","SG9999015945.SGD","LU2133065610.SGD","BK4592","LU0211326839.USD","IE00BVYPNW00.USD","LU0823399737.USD","LU1894683264.USD","SG9999011175.SGD","ABBV","LU1032955483.USD","LU0238689110.USD","LU2491050154.USD","LU2236285917.USD","LU0889565916.HKD","BK4568","LU1244550221.USD","MRK","SGXZ31699556.SGD","LU0972486137.USD","LU2237438978.USD","LU2552382215.SGD","GILD","LU0997586432.USD","LU1037948897.HKD","03165","LU2461242641.AUD","LU0820561909.HKD","AMGN"],"gpt_icon":1},{"id":"2592974594","title":"Regeneron (REGN) Valuation Check After Lynozyfic Trial Success and New Gene Writing Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2592974594","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592974594?lang=en_us&edition=fundamental","pubTime":"2025-12-18 17:22","pubTimestamp":1766049762,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has caught investors attention after unveiling promising Phase 1/2 data for its multiple myeloma candidate Lynozyfic, along with fresh progress in gene writing and high profile scientific conference appearances.\nSee our latest analysis for Regeneron Pharmaceuticals.\nThose Lynozyfic results and the new gene writing collaboration have landed against a strong backdrop, with Regeneron’s 90 day share price return of 26.66 percent pointing to building momentum. The...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-regn-valuation-check-after-lynozyfic-trial-success","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-regn-valuation-check-after-lynozyfic-trial-success","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0823434583.USD","LU0320765992.SGD","LU0053666078.USD","LU0889565916.HKD","LU1917777945.USD","LU2106854487.HKD","LU2023250504.SGD","LU2362541513.USD","LU0882574055.USD","LU0823434740.USD","REGN","BK4588","LU2089984988.USD","BK4139","LU2362541273.HKD","LU0058720904.USD","LU2468319806.SGD","BK4585","LU0114720955.EUR","LU0823416689.USD","LU2237438978.USD","LU1974910355.USD","LU0289739699.SGD","LU2362540622.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2592918196","title":"Leerink Partners Adjusts Regeneron Pharmaceuticals PT to $873 From $710, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918196","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918196?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:32","pubTimestamp":1765978333,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $802.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN","PT"],"gpt_icon":0},{"id":"2592992611","title":"Regeneron Pharmaceuticals Inc : Leerink Partners Raises Target Price to $873 From $710","url":"https://stock-news.laohu8.com/highlight/detail?id=2592992611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592992611?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:09","pubTimestamp":1765973360,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN0V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","LU2468319806.SGD","LU2106854487.HKD","LU2089984988.USD","LU0109394709.USD","LU0058720904.USD","LU2023250504.SGD","LU0823434740.USD","LU2237438978.USD","LU0823434583.USD","BK4585","LU2362540622.SGD","LU1917777945.USD","LU0889565916.HKD","BK4588","LU0882574055.USD","BK4139","LU0053666078.USD","LU0289739699.SGD","LU1974910355.USD","LU2362541273.HKD","REGN","LU0114720955.EUR","LU2362541513.USD","LU0823416689.USD"],"gpt_icon":0},{"id":"2592016955","title":"GSK wins US approval for twice-yearly asthma drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2592016955","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592016955?lang=en_us&edition=fundamental","pubTime":"2025-12-17 08:01","pubTimestamp":1765929660,"startTime":"0","endTime":"0","summary":"UPDATE 2-GSK wins US approval for twice-yearly asthma drugAdds background throughout","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL4N3XM1EK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU0345777659.USD","LU1104425308.USD","LU1496350502.SGD","LU1880407215.USD","BK4585","LU1057294990.SGD","LU1261432733.SGD","LU0784384876.USD","IE00BQJZX424.USD","LU1989771016.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU1400636574.HKD","LU0114720955.EUR","LU0985481810.HKD","LU0575583348.USD","LU0128525929.USD","LU0738911758.USD","LU0225771236.USD","LU0211326839.USD","LU1571399168.USD","LU1228905540.USD","BK4581","LU0310800379.SGD","LU2362541513.USD","LU2539964713.USD","GSK.UK","AZN.UK","LU0052756011.USD","LU2468319806.SGD","LU1481599808.USD","REGN","LU2133065610.SGD","LU2324357040.USD","LU0171293334.USD","LU0320765992.SGD","LU0310800965.SGD","LU1267930573.SGD","AMGN","SG9999013999.USD","IE0009355771.USD","LU0289739699.SGD","LU1202635105.USD","LU1267930227.SGD","LU1670756490.USD","LU0792757196.USD","LU0964806797.USD","BK5011","03165"],"gpt_icon":0},{"id":"2590071815","title":"BRIEF-EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike","url":"https://stock-news.laohu8.com/highlight/detail?id=2590071815","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590071815?lang=en_us&edition=fundamental","pubTime":"2025-12-12 23:11","pubTimestamp":1765552270,"startTime":"0","endTime":"0","summary":"BRIEF-EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's MnexspikeDec 12  - EMA's CHMP:EMA'S CHMP: RECOMMENDED GRANTING MARKETING AUTHORISATION FOR MNEXSPIKE, FOR PREVENTION OF COVID-19 IN PEOPLE FROM 12 YEARS OF AGEEMA'S CHMP: RECOMMENDED CHANGE TO EXTEND USE OF MOUNJARO FOR TREATMENT OF A TYPE OF TYPE 2 DIABETESEMA'S CHMP: EXDENSUR  RECEIVED A POSITIVE OPINIONEMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR UPLIZNAEMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR NUCALAEMA'S CHMP: ADOPTED A POSITIVE OPINION FOR MYQORZO FOR TREATMENT OF ADULTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHYEMA'S CHMP: CONCLUDES REFERRAL FOR MELATOMED, RECOMMENDS MARKETING AUTHORISATION CAN BE GRANTEDEMA'S CHMP: RECOMMENDED EXTENSIONS OF INDICATION FOR AREXVY, ASPAVELI, DOVPRELA, ELUCIREM, EYLEA, NUCALA, RECARBRIO, SIMPONI, UPLIZNA, VUEWAYFurther company coverage: MRNA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI15S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JNJ","LU1699723380.USD","LU2236285917.USD","SGXZ99366536.SGD","BK4139","LU1244550577.SGD","IE00BJJMRZ35.SGD","IE0004445239.USD","LU1302929846.USD","LU1989772923.USD","LU1934455194.USD","MRK","LU2237443978.SGD","GSK.UK","LU1430594728.SGD","LU0256863902.USD","LU1718418525.SGD","LU1732799900.SGD","IE00B775H168.HKD","LU0323591593.USD","LU2242652126.USD","MRNA","LU1066053197.SGD","CYTK","LU1023059063.AUD","LU1868836591.USD","SGXZ51526630.SGD","LU0795875169.SGD","BK4504","LU1035773651.USD","IE00BFTCPJ56.SGD","LU0417517546.SGD","LU0640476718.USD","SG9999014906.USD","LU1974910355.USD","IE00B1BXHZ80.USD","BK4505","LU0079474960.USD","LU0385154629.USD","LU1127390331.HKD","AMGN","REGN","LU0345769631.USD","LU0061475181.USD","LU0912757837.SGD","LU1093756168.USD","LU1814569148.SGD","LU2360106947.USD","SGXZ57979304.SGD"],"gpt_icon":1},{"id":"2590809502","title":"Morgan Stanley Adjusts Regeneron Pharmaceuticals PT to $768 From $767, Maintains Equalweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590809502","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590809502?lang=en_us&edition=fundamental","pubTime":"2025-12-12 22:23","pubTimestamp":1765549431,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $795.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PT","REGN"],"gpt_icon":0},{"id":"2590041825","title":"EMA Panel Recommends EU Approval of Bayer's Aflibercept 8 mg for Retinal Vein Occlusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2590041825","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590041825?lang=en_us&edition=fundamental","pubTime":"2025-12-12 22:01","pubTimestamp":1765548076,"startTime":"0","endTime":"0","summary":"The Committee for Medicinal Products for Human Use  of the European Medicines Agency  has recommended Bayer AG's aflibercept 8 mg  for marketing authorization in the European Union for the treatment of visual impairment due to macular edema following retinal vein occlusion , including branch, central, and hemiretinal vein occlusion. This would be the third indication for Eylea 8 mg in the EU. Aflibercept 8 mg, known as Eylea HD in the United States, is being jointly developed by Bayer and Regeneron. The European Commission's final decision is expected in the coming weeks.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on December 12, 2025, and is solely responsibl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDLpHLHf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","BK4585","LU2023250504.SGD","LU0889565916.HKD","LU2468319806.SGD","LU0823416689.USD","REGN","LU2362541513.USD","LU2362540622.SGD","LU0058720904.USD","LU0109394709.USD","LU2089984988.USD","LU2362541273.HKD","LU0823434583.USD","LU0053666078.USD","LU0882574055.USD","LU0823434740.USD","LU1974910355.USD","LU0320765992.SGD","BK4139","LU2237438978.USD","BK4588","LU2106854487.HKD","LU1917777945.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2590728501","title":"Ema's Chmp: Recommended Extensions of Indication for Arexvy, Aspaveli, Dovprela, Elucirem, Eylea, Nucala, Recarbrio, Simponi, Uplizna, Vueway","url":"https://stock-news.laohu8.com/highlight/detail?id=2590728501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590728501?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:35","pubTimestamp":1765546550,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI15S:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1935042991.SGD","LU0234572021.USD","GSK.UK","LU2750360997.AUD","LU0861579265.USD","LU1481599808.USD","BK4550","LU0795875169.SGD","LU2125154935.USD","LU2361044865.SGD","LU1074936037.SGD","LU0130517989.USD","LU0823416689.USD","REGN","LU0345770308.USD","LU2430703178.SGD","LU2362541513.USD","LU1309081286.SGD","LU0320765489.SGD","LU1400636574.HKD","BK4516","LU0109394709.USD","LU1244550577.SGD","IE00B3T34201.USD","LU1506573853.SGD","LU2361044949.HKD","LU0203347892.USD","LU1069347547.HKD","LU1934455277.USD","LU2471134796.USD","JNJ","LU0225771236.USD","IE00B19Z3581.USD","LU1196500208.SGD","IE00BKVL7J92.USD","LU0265550359.USD","LU1674673691.USD","LU1015430645.USD","LU0320765992.SGD","IE00BVYPNV92.GBP","LU2324357040.USD","LU1291159041.SGD","BK4588","LU1917777945.USD","MRK","LU0289739699.SGD","LU1261432733.SGD","LU1894683264.USD","SG9999015358.SGD","LU1267930813.SGD"],"gpt_icon":0},{"id":"2590508533","title":"Exclusive-U.S. FDA Presses for Reviewers to Speed up Evaluation of Eli Lilly's Weight-Loss Pill -Internal Documents","url":"https://stock-news.laohu8.com/highlight/detail?id=2590508533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590508533?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:00","pubTimestamp":1765537200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"88e4ec322662429deaabe33a5ac0ce39","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL6N3XH00W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BK4W5M84.HKD","BK4516","LU0266013472.USD","LU1093756325.SGD","IE00BK4W5L77.USD","LLY","SG9999015952.SGD","LU1323610961.USD","LU2108987350.USD","LU2361045086.USD","LU1868837136.USD","SG9999015945.SGD","LU0823416689.USD","LU2362541513.USD","LU0079474960.USD","LU0943347566.SGD","LU0432979614.USD","LU2237443465.HKD","BK4588","LU2552382058.USD","LU2237443549.SGD","LU0096364046.USD","LU0203201768.USD","LU1868836591.USD","REGN","SG9999018857.SGD","LU2087625088.SGD","LU2063271972.USD","LU0006306889.USD","SG9999015986.USD","LU0234572021.USD","LU2552382132.HKD","LU2237443978.SGD","LU2491050071.SGD","LU0289739699.SGD","LU2168563687.JPY","LU0823434740.USD","LU1057294990.SGD","LU0471298694.HKD","SG9999014914.USD","LU0466842654.USD","LU2362541273.HKD","LU2456880835.USD","LU0882574055.USD","LU0820561818.USD","IE0002141913.USD","LU0198837287.USD","LU0256863902.USD","LU0672654240.SGD","LU1868836914.USD"],"gpt_icon":0},{"id":"2590083075","title":"Exclusive-FDA Could Issue Decision on Lilly's Pill as Early as March 28 IF New Timeline Adopted","url":"https://stock-news.laohu8.com/highlight/detail?id=2590083075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590083075?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:00","pubTimestamp":1765537200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"88e4ec322662429deaabe33a5ac0ce39","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL6N3XH00W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999018857.SGD","LU2491050154.USD","LU0471298694.HKD","SG9999015952.SGD","IE00B775H168.HKD","LU2168564495.EUR","REGN","LU2168563687.JPY","LU1868837300.USD","SGXZ31699556.SGD","IE00B2B36J28.USD","LU1804176565.USD","LU2471134523.USD","LU0256863811.USD","LU1232071149.USD","BK4007","LU0354030511.USD","LU0353189763.USD","LU1974910355.USD","BK4581","LU1127390331.HKD","LU2089984988.USD","LU2746668974.SGD","LU0256863902.USD","LU1093756168.USD","LU0320765059.SGD","IE00B7KXQ091.USD","LU0203201768.USD","LU0006306889.USD","LU0466842654.USD","LU1093756325.SGD","LU0266013472.USD","LU1917777945.USD","LU2462157665.USD","LU1064131342.USD","LU1280957306.USD","BK4139","LU2456880835.USD","LLY","LU1720051108.HKD","LU2237438978.USD","LU2168564065.EUR","LU0823416689.USD","LU1551013342.USD","LU2362540622.SGD","GB00BDT5M118.USD","LU2750360997.AUD","LU0432979614.USD","LU1291159041.SGD","LU2023250504.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0355},{"period":"1month","weight":0.031},{"period":"3month","weight":0.3724},{"period":"6month","weight":0.4979},{"period":"1year","weight":0.1104},{"period":"ytd","weight":0.0941}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.529412,"avgChangeRate":0.03899},{"month":2,"riseRate":0.411765,"avgChangeRate":0.087815},{"month":3,"riseRate":0.470588,"avgChangeRate":-0.044318},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017191},{"month":5,"riseRate":0.628571,"avgChangeRate":0.057479},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.044077}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction